Pharscin Pharma received the drug re-registration approval notice
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Pharscin Pharma announced that the company recently received the "Chemical Raw Material Drug Re-registration Approval Notice" for ammonium glycyrrhizinate and the "Drug Re-registration Approval Notice" for sodium ferulate issued by the Chongqing Municipal Drug Administration. Ammonium glycyrrhizinate: raw material drug used for the production of injectable ammonium glycyrrhizinate. Sodium ferulate for injection: used for adjuvant treatment of ischemic cardiovascular and cerebrovascular diseases
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments